| Efficacy |
Proven in PID |
Proven in PID |
Proven in PID |
| Dosage |
Every 3 to 4 weeks |
Daily to biweekly |
Every 3 to 4 weeks |
| Pharmacokinetics |
High peak right after the end of infusion, rapid fall in the subsequent 48 h, and slower decline over the next 3-4 weeks |
Stable IgG serum concentrations between consecutive infusions |
Similar to IVIG but more delayed peak and slow decline over the next 3-4 weeks |
| Adverse systemic events (rate per-infusion — prescribing information) |
Frequent (17-42%*) |
Infrequent (2,5-5%**) |
Less frequent than IVIG (20%***) |
| Local site reaction |
Rare |
Frequent |
Frequent |
| IV access |
Yes |
No |
No |
| Administration |
By trained healthcare professionals only |
Self-infusion (by trained patient /caregiver) |
Self-infusion (by trained patient /caregiver) |
| Setting |
Hospital (most common), hospital outpatient, or home-based setting |
Home (most common) |
Home (most common) |
| Need to travel |
Yes |
No |
No |
| Time off from school/work |
Yes, day(s) of IVIG administration |
No |
No |
| Person managing immunoglobulin and materials supplying |
Healthcare professionals |
Patient /caregiver |
Patient /caregiver |
| IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin;fSCIG, facilitated subcutaneous immunoglobulin. *Gammagard, Privigen, Gammunex, IgVena; ** Hizentra, Cuvitru; ***Hyqvia |
